<DOC>
	<DOCNO>NCT00529516</DOCNO>
	<brief_summary>Since influenza vaccine administer every year frequent change antigenic composition , safety immunogenicity profile GSK Biologicals ' influenza vaccine GSK576389A re-evaluated repeat vaccine administration . In observer blind study , subject previously enrol study 104888 ( NCT00377585 ) receive dose 2007-2008 season 's formulation Fluarix GSK576389A . Only subject previously enrol study 104888 ( NCT00377585 ) eligible participation study .</brief_summary>
	<brief_title>Evaluate Safety &amp; Immunogenicity GSK Bio 's Influenza Vaccine GSK576389A After Repeated Vaccination Elderly Adults</brief_title>
	<detailed_description>This study involve 2 age group ( base primary study ) : Subjects enrol &gt; = 65 yr age group primary study . Subjects enrol 18-40 yrs age group primary study . The study conduct open manner age group . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . Written inform consent obtain subject . Free acute aggravation health status establish clinical evaluation enter study . If subject female , must nonchildbearing potential childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination series . Male female subject participate 104888 study ( NCT00377585 ) enrol &gt; = 65 year age group 1840 year age group . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . Planned administration vaccine foreseen study protocol 30 day vaccination Planned administration influenza vaccine study vaccine entire study period Any vaccination influenza since January 2007 Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History hypersensitivity previous dose influenza vaccine History allergy reaction likely exacerbate component vaccine ( ) Acute ( active ) clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination preexist laboratory screening test Acute disease time enrolment Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day prior vaccination , plan use study period Any medical condition IM injection contraindicate Pregnant lactate female , plan become pregnant discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Fluarix</keyword>
	<keyword>GSK Bio 's influenza vaccine GSK576389A</keyword>
	<keyword>Influenza infection</keyword>
</DOC>